US House Subpanel Would Give FDA Device Center An 8.5% Raise In 2020
A House subpanel overseeing US FDA spending approved an 8.5% boost – $33 million additional – in the agency’s device center funding for 2020, over 2019 levels.
You may also be interested in...
House Wants FDA Action On Non-Pharma Pain Relievers, Breast Density Reports, Pediatric Devices In 2020
The US House Appropriations Committee wants the FDA to foster development of non-pharma and non-opioid pain alternatives, complete mammography breast density reporting regulations, and use an additional $1m Congress would provide to conduct pediatric device trials, among other device initiatives outlined in its 2020 budget bill passed on 4 June.
The current administration would use an additional $98m in congressional budget authority in the 2020 fiscal year for FDA’s medical device efforts to modernize its regulatory approach for technology development, to enable device safety issues to be monitored more closely, and to advance new approaches for regulating digital health technologies and breakthrough devices.
US FDA Device Center program funding would see a $131m increase under the Trump administration's budget proposal, which prioritizes "speeding innovations" in medical devices and other products the agency regulates, and closely examining what regulations need to be revised, updated or eliminated.